Table 2.
The CHA2DS2-VASc score for estimating risk of stroke in patients with AF: Points are allocated by the CHA2DS2-VASc risk criteria (congestive heart failure, 1 point; hypertension, 1 point; age ≥ 75 y, 2 points; diabetes mellitus, 1 point; stroke or TIA [prior], 2 points; vascular disease [prior MI, PAD, or aortic plaque], 1 point; age 65–74 y, 1 point; sex category [ie, female], 1 point).
| CHA2DS2-VASC SCORE | ADJUSTED STROKE RATE, %/Y | RECOMMENDED THERAPY (STRENGTH OF RECOMMENDATION)* |
|---|---|---|
| 0 | 0 | ASA 75–325 mg/d or no drug therapy (level 1B) |
| 1 | 1.3 | Oral anticoagulant (level 1A) or ASA 75–325 mg/d (level 1B) |
| 2 | 2.2 | Oral anticoagulant (level 1A) |
| 3 | 3.2 | |
| 4 | 4.0 | |
| 5 | 6.7 | |
| 6 | 9.8 | |
| 7 | 9.6 | |
| 8 | 6.7 | |
| 9 | 15.2 |
AF—atrial fibrillation, ASA—acetylsalicylic acid, MI—myocardial infarction, PAD—peripheral artery disease, TIA—transient ischemic attack.
Level I evidence is evidence or general agreement that a given treatment or procedure is beneficial, useful, or effective. Level A evidence includes data derived from multiple randomized clinical trials or meta-analyses. Level B evidence includes data derived from single randomized clinical trials or large non-randomized studies.
Data from Camm et al.4